The benefits and risks of alemtuzumab in multiple sclerosis

被引：0
|
作者：
Ontaneda, Daniel [1 ]
Cohen, Jeffrey A. [1 ]
机构：
[1] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Neurol Inst, Cleveland, OH 44106 USA
来源：
EXPERT REVIEW OF CLINICAL IMMUNOLOGY | 2013年 / 9卷 / 03期
关键词：
alemtuzumab; efficacy; multiple sclerosis; risk; THERAPEUTIC LYMPHOCYTE DEPLETION; DISEASE;
D O I：
10.1586/ECI.13.1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：189 / 191
页数：3
相关论文
共 50 条
  • [31] Treatment of Multiple Sclerosis with the Interferon-βsComparative Risks and Benefits
    Robert McCulloch Herndon
    [J]. BioDrugs, 1998, 10 : 463 - 470
  • [32] Risks and benefits of multiple sclerosis therapies: need for continual assessment?
    Kieseier, Bernd C.
    Wiendl, Heinz
    Hartung, Hans-Peter
    Leussink, Verena-Isabell
    Stueve, Olaf
    [J]. CURRENT OPINION IN NEUROLOGY, 2011, 24 (03) : 238 - 243
  • [33] Current evaluation of alemtuzumab in multiple sclerosis
    Coyle, Patricia Katherine
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (01) : 127 - 135
  • [34] Alemtuzumab and multiple sclerosis: therapeutic application
    Minagar, Alireza
    Alexander, J. Steven
    Sahraian, Mohammad Ali
    Zivadinov, Robert
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (03) : 421 - 429
  • [35] Product licences for alemtuzumab and multiple sclerosis
    Coles, Alasdair J.
    Compston, Alastair
    [J]. LANCET, 2014, 383 (9920): : 867 - 868
  • [36] Treatment of multiple sclerosis with the interferon-βs -: Comparative risks and benefits
    Herndon, RM
    [J]. BIODRUGS, 1998, 10 (06) : 463 - 470
  • [37] Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
    Luciano Rinaldi
    P. Perini
    M. Calabrese
    P. Gallo
    [J]. Neurological Sciences, 2009, 30 : 171 - 173
  • [38] Benefits versus risks of latest therapies in multiple sclerosis: a perspective review
    Ontaneda, Daniel
    Di Capua, Daniela
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2012, 3 (06) : 291 - 303
  • [39] Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks
    Rinaldi, Luciano
    Perini, P.
    Calabrese, M.
    Gallo, P.
    [J]. NEUROLOGICAL SCIENCES, 2009, 30 : 171 - 173
  • [40] Alemtuzumab pharmacokinetics and pharmacodynamics in comparison of Alemtuzumab and Rebif® efficacy in multiple sclerosis
    Kovarova, I.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. P.
    Havrdova, E.
    Selmaj, K.
    Weiner, H.
    Brinar, V.
    Giovannoni, G.
    Hard, M.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Richards, S.
    Compston, A.
    [J]. JOURNAL OF NEUROLOGY, 2012, 259 : S67 - S67
12345